Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0094235

—

0f3fca45-663d-57b1-a917-e909e1c4aee8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.600
  • IL6_JAK_STAT3_SIGNALING+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.500
  • ALLOGRAFT_REJECTION+0.400
  • ANGIOGENESIS+0.400
  • COAGULATION+0.400
  • COMPLEMENT+0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
  • KRAS_SIGNALING_UP+0.400

Top 10 suppressed

  • MYC_TARGETS_V2-0.400
  • WNT_BETA_CATENIN_SIGNALING-0.200
  • HEDGEHOG_SIGNALING-0.100
  • HYPOXIA-0.100
  • MITOTIC_SPINDLE-0.100
  • MYC_TARGETS_V1-0.100
  • P53_PATHWAY-0.100
  • UV_RESPONSE_DN-0.100
  • DNA_REPAIR+0.000
  • ESTROGEN_RESPONSE_EARLY+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1GSM5359441
bladder-landscape@3
——0.852
2ERR2208908
melanoma-umap@29
——0.849
3TCGA-D8-A1JK-01A-11R-A13Q-07
breast-umap@18
—C0.849
4DRR168605
bladder-landscape@3
——0.845
5BS_KEA474HN
brain-umap@2
low-grade glioma—0.840
6BS_HJRTC9JQ
brain-umap@2
high-grade glioma—0.836
7b428d434-2904-4f67-a66f-b7928e2951e3
melanoma-umap@29
——0.833
8BS_M85CXHDV
brain-umap@2
high-grade glioma—0.833
9MDT-AP-2911
medullo-epn-umap@date-based
MedMedulloblastoma0.823
10BS_49FQXT2E
brain-umap@2
high-grade glioma—0.822

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 36 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.600Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.500Idelalisib— uncovered
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
COAGULATION0.400Binimetinib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.400Inavolisib— uncovered
KRAS_SIGNALING_UP0.400Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.400Inavolisib— uncovered
BILE_ACID_METABOLISM0.300Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
G2M_CHECKPOINT0.300Inavolisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.300Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered